Unique ID issued by UMIN | UMIN000026659 |
---|---|
Receipt number | R000030349 |
Scientific Title | Diagnosis of intestinal metaplasia in gastric mucosa uning Blue Laser Imaging(BLI) |
Date of disclosure of the study information | 2017/04/01 |
Last modified on | 2017/03/23 11:02:02 |
Diagnosis of intestinal metaplasia in gastric mucosa uning Blue Laser Imaging(BLI)
Japan BLI intestinal metaplasia Study
Diagnosis of intestinal metaplasia in gastric mucosa uning Blue Laser Imaging(BLI)
Japan BLI intestinal metaplasia Study
Japan |
Stomach tumor-related lesion
Gastroenterology |
Malignancy
NO
Clarify the usefulness of BLI images to diagnose intestinal metaplasia in the background mucosa during the detailed examination of gastric tumor.
Safety,Efficacy
Gastric biopsied specimens will be taken from the green change mucosa suspicious of intestinal metaplasia by BLI images, compared with white light images. Similarly, specimens will be taken from brown change mucosa suspicious of non-intestinal metaplasia. Based on the pathological findings, sensitivity, specificity and accuracy will be evaluated.
Based on histological assessment of endoscopically resected specimens, the usufulness of BLI will be evaluated about the extent of tumor by color contrast between the tumor and the surrounding mucosa. In additon, the color difference will be measured using a color space International Lighting Commission recommended in 1976 in order to quantify such color contast and assess visibility of tumors by BLI.
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Prevention
Maneuver |
Pathological diagnosis with endoscopy.
20 | years-old | <= |
Not applicable |
Male and Female
1) Over the 20 years old
2) Patient with gastric tumor acompanied by chronic gastric inflammatory mucosa.
1) Acute abdomen
2) Severe inflammation
3) Poor general condition patients who has risk for performing endoscopy such as ileus, perforation of intestine, pancreatitis respiratory disorder, heart failure, acquired hemophilia, stricture and large ulcer or tumor of digestive tract.
4) Patients who take peroral multiple drugs including anti-platelets and anti-coagulants, leading to difficulty to take a biopsy.
5) Patients who experienced entry of this study.
6) Patiens who is judged to be unsuitable for this clinical trial.
7) Patients who are difficult to be received the informed consent.
50
1st name | |
Middle name | |
Last name | Hiroyuki Osawa, M.D., Ph.D. |
Jichi Medical University
Division of Gastroenterology
3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498 JAPAN
0285-58-7539
osawa@jichi.ac.jp
1st name | |
Middle name | |
Last name | Masahiro Okada, M.D. |
Jichi Medical University
Division of Gastroenterology
3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498 JAPAN
0285-58-7539
r0811mo@jichi.ac.jp
Jichi Medical University
FUJIFILM MEDICAL Corporation
Profit organization
Japan
NO
2017 | Year | 04 | Month | 01 | Day |
Unpublished
Completed
2012 | Year | 05 | Month | 25 | Day |
2012 | Year | 06 | Month | 20 | Day |
2017 | Year | 03 | Month | 23 | Day |
2017 | Year | 03 | Month | 23 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000030349